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Introduction
Idiopathic intracranial hypertension (IIH) is rare disease with an incidence rate of 0.5-2.0/100,000/year 1, 2 . IIH predominantly affects obese women of fertile age 1 , whereas in the paediatric population the gender distribution is equal 1, 3 . The patients with IIH are characterised by chronic headaches, pulsatile tinnitus, diplopia, visual disturbances, bilateral papilledema, and increased intracranial pressure without hydrocephalus or intracranial mass 1, 3 . Classical neuroradiological findings include empty sella turcica, flattening of the posterior sclerae, tortuosity and distension of the subarachnoid perioptic spaces, and protrusion of the optic nerves 4, 5 .
The constantly elevated intracranial pressure threatens the visual system as ischemia from poor perfusion of the optic nerve can result in atrophy, causing permanent visual loss.
Therefore, it is paramount to recognise this rare condition early and treat it urgently, as up to 24% suffer from permanent visual loss and 4% report bilateral blindness at the final followup 1, [6] [7] [8] . The primary treatment goal for IIH is lowering the ICP with weight loss 1, 9 and acetazolamide medication 1, 10 . Acetazolamide is carbonic anhydrase inhibitor limits formation of bicarbonate and hydrogen ions, which may be the mechanism for lowering intracranial and intraocular pressure 11 . If these conservative treatments are insufficient in resolving the condition, surgical intervention is required. Neurosurgical intervention includes optic nerve sheath fenestration, shunting procedures 1, 3 as well as venous sinus stenting 12 . In severely obese patients, gastric bypass surgery may also be an effective treatment of the IIH 13, 14 .
IIH patients frequently display chronic fatigue, depression, anxiety, cognitive decline and lowered quality of life [20] [21] [22] [23] [24] [25] [26] . The comorbidity between symptoms of affective disorders and IIH could result from common biological pathways related to hypothalamus-pituitary-adrenal cortex (HPA)-axis dysfunction 16, 27 . IIH populations are also characterized by metabolic comorbidities 1, 3, 19 which may contribute to neuroendocrinological homeostasis. Although a few case studies have reported depression in association with IIH several decades ago 28 , studies have so far not attempted to evaluate the role of psychiatric disorders during the natural course of the disease. In the present study, we characterised the presence of psychiatric disorders and the usage of psychopharmaceutic medications in a well-defined IIH cohort.
J o u r n a l P r e -p r o o f
Material and methods

Study cohort
This was a retrospective study on patients with International Statistical Classification of Figure 1 ).
Clinical and Treatment variables
The following variables were used in the analyses for patients with IIH:
Before diagnosis of IIH J o u r n a l P r e -p r o o f 8. neuro-ophthalmological outcome (degree of papilledema) was classified as a) no papilledema, b) partial resolution of papilledema, and c) no improvement;
9. symptomatic outcome was characterised as follows a) symptomless, b) partial recovery,
i.e. on-going symptoms such as headache, tinnitus, fatigue, dizziness, balance problems and need for continuing medical treatment, c) no improvement.
Statistical analysis
The continuous variables were reported as means with standard deviations (SD), and the categorical variables were reported by using frequencies and percentages. 
Ethical aspects
The study has been approved by the Ethics Committee of the Kuopio University Hospital 
Results
Patient and clinical characteristics of IIH at diagnosis
A total of 51 patients were included in the study, with a mean follow-up time 
Neuro-ophthalmological and Neuroimaging Findings at diagnosis
Papilledema was found in all patients at the time of diagnosis, and bilaterally papillaedema in n=37, 72.5% of cases. Visual field defects were found in n=18 35.3% of patients. The mean visual acuity in the right eye was 1.05 (SD 0.32) and in the left 1.02 (SD 0.35). Empty sella J o u r n a l P r e -p r o o f turcica was present in 12 (23.5%), and partial empty sella in 12 (23.5%) of the cases. The flattening of the posterior globes was present in 11 (21.6%), and increased CSF around optic nerves was found in 18 (35.3%) of cases. Four (7.8%) patients had protrusion of optic nerve head, and four (7.8%) patients had increased tortuosity of optic nerve.
Psychiatric comorbidities in patients with IIH
A total of 23 (45.1%) patients with IIH had pre-existing psychiatric diagnosis ( Table 1 
Patients with IIH and psychiatric disorders at diagnosis
The IIH patients with a prior psychiatric diagnosis did not differ in age gender distribution, BMI, or OP at diagnosis from patients with IIH who had no pre-existing psychiatric comorbidity. The CSF protein count was lower for patients with psychiatric disorder, though this difference was not significant. The presenting symptoms and neuro-ophthalmological findings were similarly distributed in both groups. The patients with IIH and pre-existing psychiatric diagnosis had more often empty sella in their initial MRI when compared to the patients with IIH without psychiatric co-morbidity (34.8% vs. 14.3%, p=0.044) ( Table 2) .
Treatment types and outcomes after treatment
Acetazolamide medication was used in almost all patients (97.9%), with a mean dosage at However, when neuro-ophthalmological outcome was assessed as a degree of resolution of papilledema, the outcome was equally good for both groups, and up to 71% of all patients had physiological papillae at the end of follow-up. (p=0.405) ( Table 2 ).
Discussion
In the present study, we analysed the prevalence and the type of psychiatric disorders in the patients with IIH. We found that 45% of the patients with IIH displayed pre-existing psychiatric co-morbidities. The most common psychiatric co-morbidity was major depressive disorder (MDD), found in over 37% of the cases. Patients with IIH and pre-existing psychiatric disorder did not differ from IIH-patients with no prior psychiatric diagnoses in terms of age, sex distribution, BMI or CSF opening pressure at diagnosis. Furthermore, their symptoms at presentation and the neuro-ophthalmological findings were similar in both groups. In the patients with psychiatric co-morbidities the only difference observed at the time of IIH diagnosis was higher prevalence of empty sella on the initial MRI scan. The empty sella may reflect propensity for pituitary gland related neuroendocrinological dysfunction and contribute to the development of comorbidities of IIH, including psychiatric conditions such as the affective disorders. However, metabolomic laboratory assays were not included to this study so the extent of hormonal dysfunction could not be assessed.
The development of IIH has been suggested to be accompanied with HPA-axis dysfunction 16, 27 which has been also implicated in the pathophysiology of a variety of mood and cognitive disorders. For example, neuroendocrine studies have consistently demonstrated HPA axis dysfunction in major depression (32) . Another proposed mechanism that could explain why patients with IIH more frequently suffer from anxiety could be related to elevated catecholamine secretion observed in IIH (33) . Nevertheless, the pathophysiology of IIH is still unclear and no single theory explains how raised ICP causes the condition. Due to the young and female preponderance, neuroendocrinological dysfunction might have a pivotal role in IIH 1, 9, 15, 16 . In addition, as obesity is highly prevalent in patients with IIH, it has been suggested that metabolic, inflammatory and hormonal influences contribute to the J o u r n a l P r e -p r o o f development of IIH 1 . In particular, the dysfunction of the CSF hydrodynamics and aquaporins have been investigated as key components in understanding the aetiology of IIH 1, 3, 17, 18 .
The patients with IIH and pre-existing psychiatric disorder were treated similarly as compared to the patients without prior psychiatric diagnoses. When only neuro-ophthalmological outcome was assessed as resolution of papilledema at the end of follow-up, there was no difference in outcome between these groups. However, after the conservative treatment, or both conservative and surgical interventions combined, patients with IIH and pre-existing psychiatric diagnosis had significantly poorer overall outcome. This outcome was a combination of neuro-ophthalmological signs and subjectively reported symptoms, such as headaches, fatigue, visual disturbances. These findings suggest, that the patients with IIH and pre-existing psychiatric disorder suffer from residual symptoms more often although their papilledema has improved, and they have been treated appropriately.
Our results suggest that there is a high risk of MDD co-morbidity in patients with IIH, as recent reviews of epidemiological literature of MDD have established a global pointprevalence (current or past month) of 4.7% and a pooled period prevalence of mood disorder (point of 12-month) of 5.4% 30, 31 , as compared to our cohort the prevalence was sevenfold, 37%. There is little information as to the psychosocial impact of IIH, but there are some hypotheses on how psychiatric disorders might develop in individuals with IIH. The development of IIH has been suggested to be accompanied with HPA-axis dysfunction 16, 27 which has been also implicated in the pathophysiology of a variety of mood and cognitive disorders. For example, neuroendocrine studies have consistently demonstrated HPA axis dysfunction in major depression 32 . Another proposed mechanism that could explain why patients with IIH more frequently suffer from anxiety could be related to elevated catecholamine secretion observed in IIH 33 . MDD was common in patients with IIH and in our study the patients had received their MDD diagnoses prior to the IIH diagnosis. Depressive symptoms may represent prodromal symptoms of IIH rather than a consequence of elevated ICP, but our register-based data did not allow drawing pathophysiology-based conclusions on the causal relationships between the two conditions.
Kleinschmidt et al 20 analysed how IIH affects symptoms of depression and anxiety and quality of life in a weight-and age-matched cross-sectional study and showed the patients with IIH suffered from higher levels of depression and anxiety as compared to the control groups. These findings were reflected in poorer quality of life in patients with IIH, and illustrated more analgesics and antidepressant use in the IIH population. Depression J o u r n a l P r e -p r o o f treatment has also led to alleviation of IIH findings and subjective symptoms. Two case reports described electroconvulsive therapy improved both drug-refractory depression and IIH symptoms 35, 36 and one case reported antidepressants together with IIH treatment improved not only the IIH symptoms but also depression 37 . There are also cases when resolution of major depression has triggered IIH 28, 38 .
Our study is limited by factors inherent to a secondary analysis of retrospectively collected data as well as the small sample size. Nevertheless, there is a limited amount of previous data on this issue. This study represents a detailed investigation based on a well-defined cohort, which ensures a clinically comprehensive analysis and follow-up time for these patients, which we regard as a strength of this study. Nevertheless, further studies, focusing on the role of mental health adversities and the quality of life in patients with IIH in larger patient cohorts are needed. In 2017, we initiated a prospective collaborative multicentre study on IIH (www.iih.fi). In this study, we prospectively administer validated questionnaires, including Beck Depression Inventory, Beck's Anxiety Inventory, Perceived Stress Scale,
Headache Impact test-6 and Quality of Life (15D) questionnaires to screen and follow-up on mental well-being of patients with IIH, quality of life, and impact of their possible residual symptoms. Our aim is to increase the knowledge on pathophysiological mechanisms of IIH disease and to improve the diagnostics and management of IIH. We want to ameliorate the assessment of effectiveness of different treatment modalities, their follow-up protocol, and overall treatment outcomes. Finally, we also want to explore possible novel metabolic pathways as diagnostic or prognostic tools, and to unravel possible genomic variants of IIH.
In this prospective study, in addition to gathering all clinical variables, we perform continuous lumbar ICP measurement, collect biological samples for further metabolomics and genetic studies to advance understanding of the complex pathophysiology of the IIH disease ( Figure   2 ).
Conclusion
Almost half of the patients with IIH suffered from psychiatric disorders, and these individuals continued to have residual symptoms although their ophthalmological outcomes improved.
Psychiatric disorders appear to be common in IIH. They should be screened and treated promptly, as they may have an impact of treatment outcomes. IIH associates to neuroendocrinological disturbances, and therefore further multidisciplinary research on IIH is warranted.
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